Facebook Linkedin RSS Twitter Youtube
Home 2024

Eisai Pharmaceuticals

FDA Approves Lilly’s Amyloid-Targeting Kisunla for Early Alzheimer’s
Drug Discovery

FDA Approves Lilly’s Amyloid-Targeting Kisunla for Early Alzheimer’s

Alzheimer’s Drug Developer Alzheon Closes $100M Series E Financing
Drug Discovery

Alzheimer’s Drug Developer Alzheon Closes $100M Series E Financing

As Biopharma Giants Reshape the Field, Cognition Therapeutics Sees a Place for Its Alzheimer’s Drug
Drug Discovery

As Biopharma Giants Reshape the Field, Cognition Therapeutics Sees a Place for Its Alzheimer’s Drug

AI, Cell/Gene Therapy, Precision Medicine Drive Bullish Biotech Investment
Artificial Intelligence

AI, Cell/Gene Therapy, Precision Medicine Drive Bullish Biotech Investment

Carpenter Builds a Broad Cell Imaging Consortium to Accelerate Drug Discovery and Development
Drug Discovery

Carpenter Builds a Broad Cell Imaging Consortium to Accelerate Drug Discovery and Development

ImmunoGen Shares Plunge after Phase III Failure of Lead ADC in Ovarian Cancer
Cancer

ImmunoGen Shares Plunge after Phase III Failure of Lead ADC in Ovarian Cancer

“Some Hope”: Biogen, Eisai Release Positive Phase II Results for Alzheimer’s Candidate
Industry News

“Some Hope”: Biogen, Eisai Release Positive Phase II Results for Alzheimer’s Candidate

Dr. Reddy’s Buys Ex-Asia Rights to Eisai Cancer Candidate E7777
Cancer

Dr. Reddy’s Buys Ex-Asia Rights to Eisai Cancer Candidate E7777

Valeant Buys Targretin’s U.S. Rights from Eisai for $65M+
Cancer

Valeant Buys Targretin’s U.S. Rights from Eisai for $65M+

FDA Clears Eisai’s Epilepsy Drug Fycompa
News

FDA Clears Eisai’s Epilepsy Drug Fycompa

12Page 1 of 2
Copyright © 2024 Genetic Engineering & Biotechnology News. All Rights Reserved.